Anti-NGF antibodies and their use

US10093725B2 · kind B2 · utility

Assignee

• Zoetis Belgium S.A · BE

Inventors

• Susan E. Lacy · Shrewsbury, US
• Jeffrey A. Barbon · Groton, US
• Meha Chhaya · Shrewsbury, US
• Emma Fung · Northborough, US
• Charles W. Hutchins · Libertyville, US
• Diane M. Lang · Hope Valley, US
• Eve H. Barlow · Princeton, US
• Mary Leddy · North Attleborough, US
• Ravi Chari · Norwich, US

Key dates

• Filing date: Jul 14, 2015
• Grant date: Oct 9, 2018
• Expiry date: Jul 14, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.